Thai Union, S2G Ventures among new investors in aquaculture biotech firm ViAqua

Published on
June 10, 2021
Biotech firm ViAqua aims to improve shrimp health and combat disease with its RNA-particle platform.

Biotechnology company ViAqua Therapeutics announced that its recently-completed 4.3 million (EUR 3.5 million) funding round will be used to support the commercialization of its first product dedicated to improving shrimp health …

Photo courtesy of ViAqua Therapeutics

Want seafood news sent to your inbox?

You may unsubscribe from our mailing list at any time. Diversified Communications | 121 Free Street, Portland, ME 04101 | +1 207-842-5500